Posts Tagged ‘GLP-1 agonists’

The acute shortage of obesity medicines is over. But in absolute terms we are still operating with a mindset of scarcity when thoughts turn to obesity care. Policy often dictates limited access to care and even more so, to medicines that can so effectively treat this condition. What happens if we start thinking in terms […]

At FNCE yesterday, the Weight Management practice group presented the changing role of dietitians in weight management with remarkable clarity – something GLP-1s are bringing at a dizzying pace. Colleen Tewksbury summed up the very essence of this change, saying: “We are shifting the focus from quantity to quality of nutrition in weight management.” It […]

Honestly, there is so much glaring, blinding irony in the news these days that this one almost slipped by us. Costco makes its money from selling people ginormous packs of food, but now the chain is getting into the action on GLP-1s by selling them at the discounted price of $499 per month. Both Ozempic […]

In the International Journal of Obesity, obesity medicine physician and researcher Caroline Apovian offers a compelling case to favor a prediabetes indication for GLP-1s. She writes: “The approval of a GLP-1 for prediabetes will change the landscape for prevention of T2DM and its complications due to early detection. Currently, most individuals at risk of T2DM […]

Back in March 2024, we welcomed the news of a door opening ever so slightly for Medicare Part D plans to cover GLP-1s in people with obesity and heart disease. So 18 months later, it’s reasonable to ask, how’s that working out for everyone? A new research letter in JAMA gives us an answer, but […]

Today at EASD, investigators for the ATTAIN-1 pivotal phase three trial are presenting detailed results for orforglipron in obesity. These results, published yesterday in the New England Journal of Medicine, offer no big surprises. The effectiveness in this 72-week trial was acceptable. But a big question hangs in the air. Will orforglipron be the GLP-1 […]

Today in Nature Medicine, compelling new research tells that long-term outcomes with metabolic surgery are superior to the outcomes with GLP-1 agonists in persons with diabetes and obesity. These are impressive and important results. But we have to wonder if anyone is really listening. The enthusiasm for advanced obesity medicines is so great that many […]

The attention economy has been getting a lot of, well, attention lately. In fact, the phenomenon is nothing new. People have been competing for the attention of Americans since the rise of cheap daily newspapers in the 19th century. But lately it seems that the quest to command attention is taking over more and more […]

The short supply, high prices, and despicable insurance restrictions for advanced obesity medicines have created many problems. For example, compounding of these medicines has been and continues to be controversial – for good reasons. Now, FDA is recognizing one of the most pernicious threats to emerge from this situation – sketchy sellers of “research” peptides. […]

Sisyphus, the myth of a person condemned to a futile task of rolling a boulder uphill for eternity, has long been an apt metaphor for obesity medicine. He still is, said Donna Ryan yesterday at the Louisiana 2025 Obesity Conference in New Orleans. But the narrative has shifted dramatically, she explained. Before this shift, the […]